About ENFEXIA
ENFEXIA 500 mg is a pharmaceutical-grade ciprofloxacin formulation manufactured by Bilim for laboratory investigation of fluoroquinolone antibacterial mechanisms. Ciprofloxacin belongs to the fluoroquinolone class of antimicrobial agents, widely studied for its broad-spectrum activity against gram-positive and gram-negative bacterial pathogens. Research scientists examining antimicrobial resistance patterns, bacterial DNA gyrase inhibition, and topoisomerase IV interactions will find this standardised preparation valuable for controlled experimental protocols.
The compound’s mechanism involves selective targeting of bacterial DNA replication machinery, specifically inhibiting DNA gyrase and topoisomerase IV enzymes essential for bacterial chromosome replication and segregation. Laboratory studies investigating bacterial resistance mechanisms, efflux pump activity, and plasmid-mediated quinolone resistance rely on authentic pharmaceutical preparations like ENFEXIA for consistent research outcomes. Researchers at Stroid UK Shop can access this preparation alongside complementary research compounds from our antibacterial research category.
Laboratory Applications
Ciprofloxacin research encompasses multiple investigational areas including antimicrobial susceptibility testing, resistance gene expression analysis, and bacterial biofilm formation studies. The 500mg tablet formulation enables precise dosing calculations for in-vitro bacterial culture experiments and resistance development protocols. Microbiological research teams study ciprofloxacin’s activity against various bacterial species, including Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus strains.
Pharmacokinetic research applications include investigating drug metabolism pathways, tissue distribution patterns, and excretion mechanisms in experimental models. The standardised ENFEXIA formulation provides consistency for comparative studies examining fluoroquinolone structure-activity relationships. Researchers also investigate interactions between ciprofloxacin and other antimicrobial agents, examining synergistic or antagonistic effects in combination therapy protocols. Our research catalogue includes selective androgen receptor modulators and research peptides for comprehensive experimental programmes.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Ciprofloxacin HCl |
| Strength | 500mg per tablet |
| Manufacturer | Bilim Pharmaceuticals |
| Formulation | Film-coated tablets |
| CAS Number | 85721-33-1 |
| Molecular Formula | C₁₇H₁₈FN₃O₃·HCl |
| Storage Conditions | Room temperature, dry environment |
| Intended Use | Laboratory research only |
Research Compliance
ENFEXIA 500mg ciprofloxacin tablets are supplied exclusively for in-vitro laboratory research and analytical purposes. This product is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure proper laboratory protocols, appropriate disposal methods, and compliance with institutional safety guidelines when handling fluoroquinolone compounds. All experimental work should be conducted in appropriate laboratory facilities with suitable containment and safety measures.
